Quality by design (QbD) is a systema�c approach to product development that begins with predefined objec�ves and emphasizes product and process understanding and controls based on sound science and quality risk management (ICH Q8). The emphasis of QbD began with the recogni�on that increased tes�ng does not essen�ally improve product quality; however, quality must be built into the product. The regulatory agencies encourage risk-based approaches and the adop�on of QbD principles in drug product development and manufacturing. At Piramal we are applying QbD approach in product development, which is characterized by following principles:
• Designing product and its manufacturing process to meet pa�ent needs with respect to safety and efficacy • Designing manufacturing process to consistently produce product mee�ng pre-defined quality criteria
• Understanding impact of input parameters on product quality to adequately build the controls at the cri�cal points in the process
QbD principally is a scien�fic, logical, and preemp�ve scheme that will incorporate quality control into each and every step of drug development and the manufacturing process. It is a target-oriented approach which we define Quality Target Product Profile (QTPP) at ini�al stages of product development. The QTPP describes the desired performance based on intended clinical aspects, dosage strength, delivery mode, pharmacokine�cs, drug product quality criteria and the container closure system. The next step is iden�fica�on of key elements of QbD as follows:
Cri�cal Quality A�ributes (CQA):
A CQA is a physical, chemical, biological, or microbiological characteris�c of an output drug product that should be within an appropriate limit to ensure the desired product quality. The quality a�ributes of a drug product may include iden�ty, assay, content uniformity, degrada�on products, residual solvents, drug release, moisture content, microbial limits, and physical a�ributes such as color, shape, size, odor, score configura�on, and friability. These a�ributes can be cri�cal or not cri�cal. Cri�cality of an a�ribute is mainly based upon its influence on the safety and efficacy in the pa�ent.
Risk Assessment:
There are many a�ributes of the drug substance and excipients that could poten�ally impact the CQAs of the intermediates and finished drug product. It is different levels (high, medium, and low), decision on ac�on/inves�ga�on required to mi�gate that risk will be considered.
Cri�cal Material A�ributes (CMA):
A CMA of a drug substance, excipient, and in-process materials is a physical, chemical, biological, or microbiological characteris�c of an input material that should be consistently within an appropriate limit to ensure the desired quality of that drug substance, excipient, or in-process material. The CMA is likely to have an impact on CQA of the drug product.
Cri�cal Process Parameters (CPP):
A CPP of manufacturing process are the parameters which, when changed, can poten�ally impact product CQA and may result in failure to meet the limit of the CQA.
Design Space:
As per ICH Q8, this is the mul�dimensional combina�on and interac�on of input variables (e.g., process. Design space is proposed by the applicant and is subject to regulatory assessment and approval.
Control Strategy:
Based on process and product understanding, during product development sources of variability are iden�fied. Understanding the sources of variability and their impact on processes, in-process materials, and drug product quality can enable appropriate controls to ensure consistent quality of the drug product during the product life cycle. (Figure 1 ). Considering 3 different levels (high, medium, and low), decision on ac�on/inves�ga�on required to mi�gate that risk will be considered.
Design of Experiment (DoE):
This is a systema�c approach applied to conduct experiments to obtain maximum output. We have capability and exper�ze to perform DoE in product development using so�ware like Minitab and Sta�s�ca.
Design of experiments-screening: Designs applied to screen large number of factors in minimal number of experiments to iden�fy the significant ones. Main purpose of these designs is to iden�fy main effects and not the interac�on effects. For such studies common designs used are Placke�-Burman and frac�onal factorial design.
Design of experiments-op�miza�on: Experimental designs considered to carry out op�miza�on are mainly full factorial design, surface response methodology (e.g. Central composite, Box-Behnken), and mixture designs. These designs include main effects and interac�ons and may also have quadra�c and cubic terms require to obtain curvature. These designs are only applied once selected factors are iden�fied, which seem to be contribu�ng in process or formula�on.
Risk assessment methodology:
Cause and Effect Diagrams (fish bone/Ishikawa): This is very basic methodology to iden�fy mul�ple possible factors for a single effect (Figure 3 ). Various cause associated with single effect like man, machine, material, method, system, and environment need to be considered to iden�fy root cause.
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TOOLS APPLIED IN QBD APPROACH
Primary branch represents effect, whereas major braches in diagram are associated with major causes and minor branches supports the possible detailed cause.
Failure Mode Effect Analysis (FMEA): This is an important tool to evaluate poten�al failure modes in any process.
Quan�fica�on of risk by interac�on of probability func�ons of severity, occurrence, and detectability of any event can be done. FMEA can be effec�vely performed with good understanding of process.
PAT:
Control Strategy: Assurance of product quality during intermi�ent steps using Process Analy�cal Technology blending and wet granula�on. These technologies further make assurance of con�nuous improvement in process and product quality through its life cycle.
To summarize, the aim of implemen�ng pharmaceu�cal QbD is to reduce variability and defects in product, 
